14.4 Cervical Screening (CervicalCheck), Colposcopy Referrals, and Gynaecological Malignancies
Key Takeaways
CervicalCheck uses primary high-risk HPV testing from ages 25 to 65 in its routine population. With a negative routine HPV result, recall is three years at ages 25–29 and five years at ages 30–65.
For an initial routine HPV-positive result with normal reflex cytology, repeat the screening test in 12 months. Abnormal cytology with HPV or a persistently positive HPV test at the 12-month repeat leads to colposcopy.
Investigate unexplained bleeding or discharge as symptoms. A cervix suspicious for cancer warrants urgent referral to colposcopy without taking a screening sample. With a normal-appearing cervix, investigate other causes and refer to gynaecology when symptoms remain unexplained.
Irish postmenopausal bleeding guidance recommends sampling at an endometrial thickness of 4 mm or greater. Hysteroscopy is indicated above 4 mm or with focal pathology. Reassess unexplained recurrent bleeding even after an initially reassuring investigation.
Ascites or a suspicious pelvic mass merits prompt gynaecological oncology referral. Use symptoms, examination and ultrasound together. RMI I multiplies the ultrasound score, menopausal score and serum CA-125, with referral thresholds dependent on the named pathway.
CervicalCheck and HPV prevention
CervicalCheck is Ireland's organised cervical screening programme. Its routine population is people with a cervix aged 25–65 who are eligible for screening. In March 2020 the programme moved to primary high-risk HPV testing. Follow the programme's result letter and individual plan, particularly after previous abnormal results or treatment. Age bands describe routine recall. They are separate from any ongoing diagnostic or specialist follow-up.
| Routine age at screening | Recall interval after a negative HPV result |
|---|---|
| 25–29 years | Three years |
| 30–65 years | Five years |
The laboratory tests for high-risk HPV first. If HPV is found, it examines the same sample for abnormal cells by reflex cytology. A positive HPV result indicates a risk that needs triage. It does not diagnose CIN or cancer. If HPV is not found in a routine sample, cytology is not usually performed. A negative screening result reduces future risk but cannot exclude cancer in a patient with symptoms.
Persistent high-risk HPV causes most cervical cancers, including through types 16 and 18. Some cervical cancers are HPV-independent. The HSE school programme offers Gardasil 9 in first year of secondary school. Vaccination reduces risk and eligible vaccinated people should still participate in screening.
Apply cervical screening eligibility in gender-diverse care
Use the language the patient prefers and ask privately about anatomy or relevant treatment only when it informs care. Explain why the information matters, check consent and offer a chaperone for an intimate examination. A trans man who retains a cervix can be eligible for CervicalCheck. People registered as male with the Department of Social Protection may not appear on the automatic register. Help an eligible patient to contact CervicalCheck or a registered provider to arrange access. New symptoms require assessment through the diagnostic pathway.
For patients seeking medical transition, discuss their goals and existing care. A doctor registered with the Medical Council can refer an Irish resident aged 17 or older to the National Gender Service waiting list for its adult pathway. Blood tests, a diagnosis of gender dysphoria and a separate mental health referral are not required to make the referral. The specialist team assesses what care the person needs. Continue routine primary care while they wait. The HSE National Clinical Programme is developing a model of care and directs clinical queries to the treating GP or healthcare provider.
HSE CervicalCheck register · CervicalCheck inclusive practice guidance · HSE gender healthcare · National Gender Service referral criteria
Routine screening results and diagnostic referral
- HPV detected and no abnormal cells: Repeat cervical screening in 12 months. If HPV is still detected, refer for colposcopy even if repeat cytology is normal. A negative HPV result at routine repeat returns to the age-based interval unless separate follow-up applies. A negative test can reflect cleared infection or HPV below detection, so interpret the result by the programme rather than assuming permanent immunity.
- HPV detected and abnormal cells: Colposcopy is indicated. The National Screening Service assigns referral priority by result. Colposcopy quality standards target an appointment within two weeks when invasive cancer is suspected clinically or by screening, within four weeks for high-grade squamous or any glandular abnormality, and within eight weeks for other referrals. This includes the distinction between low-grade changes and HSIL, ASC-H or glandular changes.
- Inadequate or unsatisfactory sample: Follow the result instructions and repeat after at least three months. Refer after three consecutive inadequate results.
Evaluate symptoms on a separate clinical pathway
Postcoital or intermenstrual bleeding, persistent unusual discharge or pelvic pain calls for history and examination, usually including speculum and pelvic examination with consent. Consider pregnancy, infection and benign cervical or uterine causes as appropriate. A recent negative HPV screen does not explain symptoms.
A cervix suspicious for cancer needs an urgent referral to the nearest colposcopy unit without a screening sample. If the cervix appears normal or a benign explanation is likely, take a routine screen if the patient is due, and pursue diagnostic assessment in parallel. Persistent unexplained symptoms may need an ambulatory or general gynaecology referral. A screen taken because it is due does not resolve the diagnostic work-up.
Worked distinction: An asymptomatic patient with a routine HPV-positive result and no abnormal cells is recalled in 12 months. A patient with postcoital bleeding and a friable, ulcerated lesion goes urgently to colposcopy for diagnostic assessment even after a negative screening result.
Colposcopy and cervical intraepithelial neoplasia (CIN)
Colposcopy uses magnification to examine the cervix and assess the transformation zone near the squamocolumnar junction. The colposcopist documents the visible limits of the transformation zone, the location and extent of lesions and any signs of invasion. Acetic acid can make abnormal epithelium turn white. Dense acetowhitening with coarse punctation or mosaicism is concerning. Lugol iodine stains glycogen-rich mature squamous epithelium dark. An area that does not stain can be abnormal, although columnar and immature epithelium can also fail to stain. Directed biopsy and histology establish the grade where required.
Interpret histology and plan follow-up
- CIN 1: Low-grade change limited mainly to the lower epithelial third. After a low-grade referral with CIN 1 or less on biopsy, CervicalCheck usually recommends surveillance with repeat screening in 12 months. High-grade cytology with low-grade biopsy results requires senior review and may need MDT discussion or excision. Check whether the full lesion was visible.
- CIN 2: High-grade change, usually extending through roughly two thirds of the epithelium. Treatment may be indicated. Selected patients may be observed by an experienced colposcopist after satisfactory assessment and confirmation by biopsy, with invasion, glandular disease and CIN 3 excluded, and reliable follow-up. In the Irish programme offer treatment if CIN 2 has not resolved after 24 months and treat progression to CIN 3.
- CIN 3: Severe intraepithelial abnormality that can extend through the full epithelial thickness. It has not invaded the underlying stroma. The Irish programme recommends treatment for confirmed CIN 3, with a specific pregnancy pathway. If invasion is suspected in pregnancy, obtain specialist assessment promptly.
- Excision and surveillance: LLETZ uses a wire loop to remove the transformation zone for histological assessment, including margins. Deeper or repeated excisions can increase subsequent preterm birth risk. Agree treatment and follow-up with colposcopy. CervicalCheck generally uses an HPV test of cure at six to nine months after treatment for CIN. Follow the specific plan for glandular disease or hysterectomy.
A screen identifies risk. A colposcopic impression identifies where to sample. Histology assesses epithelial disease and whether invasion is present. Each step informs the next decision.
| Cancer | Presentation that should prompt assessment | Diagnostic and treatment decisions |
|---|---|---|
| Cervical | Postcoital, intermenstrual or postmenopausal bleeding, persistent abnormal discharge or a suspicious cervical lesion | Urgent colposcopy when invasive cervical disease is suspected. Biopsy for diagnosis. Clinical findings and imaging inform FIGO stage. |
| Endometrial | Unexplained postmenopausal bleeding, with or without endometrial risk factors | Follow the Irish postmenopausal bleeding pathway. Histology establishes the diagnosis, and pathological and molecular findings guide treatment. |
| Tubo-ovarian | Persistent distension, early satiety, pelvic pain, urinary urgency or frequency, ascites or pelvic mass | Use symptoms, examination, CA-125 and ultrasound as appropriate. Refer concerning findings for specialist staging and MDT treatment planning. |
| Vulval | Persistent itch, local pain, a non-healing ulcer, indurated plaque or new lump | Examine the vulva and refer suspicious lesions for punch or incisional biopsy. Histology, tumour location, size and invasion guide surgery and nodal management. |
Treatment principles for invasive cervical cancer
Tissue establishes invasion and tumour type. Specialist assessment includes pelvic MRI where appropriate for local extent, and CT or PET-CT in relevant stages or with suspicious nodes. Selected very early tumours may be treated with conisation or simple hysterectomy. The 2026 ESMO guideline supports less radical surgery for specified low-risk early cancers with nodal assessment when indicated. Other operable early cancers may require more extensive surgery. Locally advanced disease generally needs concurrent chemoradiotherapy including brachytherapy. Weekly cisplatin with radiotherapy is an Irish NCCP regimen for eligible patients. Fertility goals, tumour size, invasion and nodal findings matter to the treatment decision.
Endometrial cancer and postmenopausal bleeding
Postmenopausal bleeding (PMB) is vaginal bleeding after at least 12 months without menstruation due to menopause. Endometrial atrophy, genitourinary atrophy and polyps are common benign causes. Endometrial malignancy or hyperplasia must be considered, as must vaginal, vulval or cervical lesions. Check whether the blood might be from the urinary or gastrointestinal tract.
The Irish National Clinical Practice Guideline recommends a focused history and examination including speculum and vaginal assessment before referral. All PMB outside HRT requires referral for investigation. An ambulatory or fast-track gynaecology pathway is preferred, with a national guideline target for review within 28 days. Excessive bleeding, haemodynamic change or another acute concern requires immediate assessment on clinical grounds.
Thickness guides sampling and hysteroscopy
Transvaginal ultrasound assesses the endometrium's thickness and appearance. Where the endometrium is fully visible, measure the thickest double layer in the mid-sagittal plane. Under the Irish guideline:
- 4 mm or greater in PMB: Obtain an endometrial sample. At exactly 4 mm, the sampling threshold is met.
- More than 4 mm or focal pathology: Perform diagnostic hysteroscopy. Hysteroscopy visualises the cavity and facilitates directed sampling of a focal lesion. A technically limited image or non-visualised endometrium requires further assessment, not a low-risk interpretation.
- Less than 4 mm, fully visualised and normal in appearance: A reassuring finding in an initial assessment. Persistent, recurrent or unexplained bleeding after reassuring investigations warrants re-evaluation. Consider hysteroscopy and repeat biopsy with consultant input.
- Tamoxifen and abnormal uterine bleeding: Offer diagnostic hysteroscopy and endometrial sampling, alongside transvaginal ultrasound. Ultrasound thickness alone is unreliable for triage in this setting.
- HRT: Distinguish expected scheduled bleeding on sequential HRT from persistent, irregular, heavy or prolonged bleeding. Investigate bleeding on continuous combined HRT beyond six months or after established amenorrhoea, and consider earlier referral when risks or symptoms warrant it.
Worked distinction: PMB with a diffusely 4 mm lining meets the sampling threshold. PMB with a 3 mm measurement and a focal lesion still calls for hysteroscopy. The size and appearance answer different questions.
Endometrial cancer risk and treatment
Risk factors include obesity, older age, chronic anovulation such as in PCOS, systemic unopposed oestrogen with an intact uterus, tamoxifen exposure and inherited susceptibility. In many endometrioid cancers, sustained oestrogen exposure without adequate progestogenic opposition promotes endometrial proliferation. Histological type and molecular profile are relevant beyond that pathway.
Lynch syndrome: Pathogenic mismatch-repair variants increase the risk of endometrial and other cancers. Mismatch-repair tumour testing helps identify people who need genetic counselling and possible germline testing. The 2025 ESGO–ESTRO–ESP guideline considers surveillance and risk-reducing surgery. Timing and whether to remove ovaries depend on the particular variant, reproductive plans and impact of early menopause. Counsel about promptly reporting bleeding even where surveillance is offered.
After diagnosis: Specialist assessment integrates histology, molecular classification where available and stage. For suitable patients, usual initial surgery includes total hysterectomy with bilateral salpingo-oophorectomy and risk-directed nodal evaluation, which can include sentinel nodes. Adjuvant treatment depends on recurrence risk. Selected patients who wish to preserve fertility require a specialist fertility-sparing pathway. Distinguish histological confirmation from screening or assessing risk.
Epithelial tubo-ovarian cancer
Many high-grade serous cancers are thought to begin in the fallopian tube fimbria. The primary site, histology and genetic profile affect how disease is classified and treated. Ask about family history of ovarian, breast and related cancers.
Presentations in primary care
Consider ovarian cancer in persistent or frequent abdominal distension, early satiety, reduced appetite, pelvic or abdominal pain, and urinary urgency or frequency, especially with new symptoms after age 50. Unexplained weight loss, fatigue or new bowel symptoms may add concern. Differentiate recurrent meal-related symptoms from ongoing progressive distension. Examine for ascites and an abdominal or pelvic mass.
The Irish NCCP GP pathway supports direct urgent gynaecological oncology referral for unexplained ascites, a concerning pelvic mass, or ultrasound suspicious of ovarian cancer. If symptoms are suspicious and examination is normal, it uses CA-125 to guide next steps. In the NCCP pathway, 35 kU/L or greater prompts pelvic ultrasound and more than 200 kU/L prompts urgent oncology referral. A rising CA-125 despite normal ultrasound also needs evaluation under that pathway. Persistent symptoms require reassessment even with initially reassuring results. NICE NG12 uses distinct age-specific CA-125 thresholds for primary care. These thresholds address separate health systems.
Adnexal masses, RMI I and specialist decisions
Serum CA-125 can rise with ovarian cancer and with non-malignant conditions, including endometriosis, fibroids or ascites of other causes. A normal result cannot rule out an ovarian malignancy. Ireland's National Clinical Guideline No. 20 recommends transvaginal and transabdominal ultrasound and IOTA Simple Rules in conjunction with clinical assessment for suspected ovarian carcinoma. Suspicious findings include irregular solid tissue, ascites and papillary projections. Indeterminate lesions may need expert ultrasound or MRI where it changes management. The guideline recommends contrast CT of the thorax, abdomen and pelvis for staging.
Risk of Malignancy Index I is a secondary-care tool used in some adnexal-mass pathways:
- Count one feature each for multilocularity, solid areas, bilateral lesions, ascites and intra-abdominal metastases. The ultrasound multiplier U is 0 with no features, 1 with one feature and 3 with two to five.
- The menopausal multiplier M is 1 before menopause and 3 after menopause. In named pathways a woman older than 50 after hysterectomy is classified as postmenopausal for this calculation.
- Use the measured serum CA-125 value in U/mL. Do not substitute a threshold or add the three components.
RCOG Green-top 34 for postmenopausal cysts uses RMI I ≥200 for further specialist assessment. NICE CG122 uses ≥250 for MDT referral. The National Maternity Hospital describes scores over 200 as highly suspicious. In Ireland use the applicable service's pathway and the clinical and ultrasound findings. Ascites and suspicious morphology justify referral without waiting to reach a score cutoff.
For an already postmenopausal patient with one ultrasound feature and CA-125 of 60 U/mL, the index is . With two ultrasound features it is . Reassess the actual features and symptoms rather than making the result the sole determinant of referral.
The specialist team establishes the diagnosis and stage and considers germline testing appropriate to subtype. In advanced epithelial disease, cytoreductive surgery aims for no visible residual tumour when feasible. Some patients undergo primary surgery. Others receive neoadjuvant platinum-based chemotherapy followed by interval surgery if appropriate, depending on resectability and fitness. Referral for assessment does not dictate which sequence will be chosen.
Vulval symptoms, lichen sclerosus and malignancy
Examine new or persistent vulval itching, ulcers, painful areas and palpable lesions. Consider dermatitis, candidiasis, a Bartholin duct cyst or abscess and other infectious or inflammatory causes. A persistent new Bartholin-area mass in a postmenopausal patient needs specialist assessment. Suspicion increases with a non-healing ulcer, induration, spontaneous bleeding or changing architecture.
Lichen sclerosus can cause itch, soreness, pale plaques, fissures and loss of vulval architecture. Treatment with a potent or ultrapotent topical corticosteroid such as clobetasol and follow-up help control disease. A new focal thickening or non-healing ulcer within affected skin needs assessment for malignancy. Vulval squamous carcinomas include HPV-associated disease and HPV-independent disease associated with differentiated VIN and often chronic dermatosis.
Refer a suspicious lesion for diagnostic punch or incisional biopsy with documentation of the site and specialist MDT assessment. ESGO recommends aiming for tumour-free margins. Groin nodal treatment depends on depth, size, focality and clinical nodes. An eligible unifocal tumour under 4 cm with invasion above 1 mm and no suspicious nodes can be considered for sentinel node assessment. The need for more extensive groin treatment is decided by the specialist team.
A 32-year-old asymptomatic woman attends general practice for a due routine CervicalCheck screen. She has never been treated for a cervical abnormality and this is her first HPV-positive result. This sample detects high-risk HPV, and reflex cytology finds no abnormal cells. What follow-up should the practice arrange under the routine programme algorithm?
Refer immediately for urgent colposcopy and cervical biopsy
Repeat cervical screening (HPV testing) in 12 months
Discharge to routine 5-year screening recall
Perform immediate Large Loop Excision of the Transformation Zone (LLETZ)
A 58-year-old woman presents to the rapid-access gynaecology clinic reporting two episodes of light, painless vaginal bleeding over the preceding 3 weeks. Her menopause occurred at age 51, and she has had no vaginal bleeding for the past 7 years. She has never taken hormone replacement therapy. Her BMI is 34 kg/m2. Speculum examination confirms light blood in the vaginal vault with a healthy-appearing, smooth cervix. Bimanual examination reveals a mobile, non-tender, normal-sized uterus. A transvaginal ultrasound demonstrates an anteverted uterus with an endometrial thickness measured in the mid-sagittal plane of 7 mm. What is the most appropriate immediate next step?
Reassure the patient that bleeding is due to senile atrophic vaginitis and prescribe topical vaginal oestrogen cream
Schedule a repeat transvaginal ultrasound in 3 months to monitor for endometrial progression
Arrange diagnostic hysteroscopy with endometrial sampling
Perform immediate bilateral uterine artery embolisation
A 62-year-old postmenopausal woman presents with a 3-month history of persistent abdominal fullness, early satiety, and increased abdominal girth. On examination, there is mild abdominal distension with shifting dullness and an ill-defined, non-tender mass palpable in the left adnexa. A pelvic ultrasound reveals a multilocular left ovarian cystic mass measuring 8 cm with irregular solid components and moderate free ascites in the pouch of Douglas. Her serum CA-125 is elevated at 180 U/mL. What is her calculated Risk of Malignancy Index (RMI) score, and what is the appropriate management pathway?
RMI score 180; arrange conservative follow-up with repeat ultrasound in 6 weeks in the community
RMI score 540; schedule laparoscopic left ovarian cystectomy at a local community hospital
RMI score 1,080; refer to a gastroenterology clinic to investigate suspected irritable bowel syndrome
RMI score 1,620; refer urgently to a tertiary specialist gynaecological oncology centre
A 34-year-old trans man with a cervix has no symptoms and is due for routine screening. He is registered as male with the Department of Social Protection and has not received an invitation. What is the best response?
Explain that he can be eligible and help him contact CervicalCheck or a registered provider to arrange screening
Assume that he is ineligible based on the administrative record
Refer for cancer diagnosis solely because the invitation did not arrive
Ask him to wait for a future gender healthcare model before discussing screening
Sections you finish are checked off in the contents.